EVOTEC SE HIGHLIGHTSEVOTEC CONTINUES ITS STRONG ORGANIC REVENUE GROWTH IN ALL BUSINESS AREAS
Group revenues increased by 24% to
Continued strong revenue growth momentum: Total EVT Execute revenues (incl. intersegment revenues) up 26% to
Reported adjusted Group EBITDA totalled
Other non-operating result of
NEW AND EXTENDED ALLIANCES REFLECT SUCCESS OF GROWTH STRATEGY
Significant operational and scientific step-up of targeted protein degradation alliance with
Several new integrated drug discovery collaborations signed, including INDiGO, CMC and DMPK agreements
New collaborations signed, based on unique, data-driven platforms with Almirall (dermatology),
Just - Evotec Biologics: Just -Evotec Biologics is currently in its initial build up phase. Strategic investments into disruptive technology platform show good progress - foundation laid for accelerated revenue growth; multiple new development and manufacturing agreements, e.g., among others with
Co-owned pipeline projects progressing well, e.g. Phase II start of BAY 2395840 (diabetic neuropathic pain), expansion with JingXin for EVT201, submission for approval in
Successful expansion of the EVOequity portfolio with new strategic equity stakes in several promising companies such as Centauri, IMIDomics,
Launch of Aurobac Therapeutics, a joint venture with
CORPORATE
Effective
Signing of definitive agreement to acquire the cell technology company Rigenerand Srl, a leader in the field of cGMP manufacturing of cell therapies, which will operate as Evotec (Modena) Srl
Annual General Meeting 2022: Approval of all proposed agenda items; Camilla Macapili Languille elected to the Supervisory Board
BUSINESS OUTLOOK FOR FULL-YEAR 2022 REFINED AND MID-TERM TARGETS 2025 CONFIRMED
Group revenues now expected to be in a range of
Adjusted Group EBITDA expected to be unchanged in the range of
Unpartnered research and development expenses expected to be in a range of
Mid-term goals target revenue growth to more than
The forecast takes in account - as far as possible - the current increased global uncertainties related to e.g. the COVID-19 pandemic and the war in
More detailed information and financial tables are available in our half-year report published on the Evotec website under the following link: https://www.evotec.com/en/investor-relations/publications
Webcast/Conference Call
The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English.
Conference call details
Date: Thursday,
Time:
From
From
From
From
From
Access Code: 37893553#
A simultaneous slide presentation for participants dialling in via phone is available at https://www.webcast-eqs.com/evotec20220811/no-audio.
Webcast details
To join the audio webcast and to access the presentation slides you will find a link on our homepage www.evotec.com shortly before the event.
The on-demand version of the webcast will be available on our website: https://www.evotec.com/en/investor-relations/publications.
FORWARD-LOOKING STATEMENTS
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'should,' 'target,' 'would' and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact:
T: 49 (0)40 56081-222
(C) 2022 Electronic News Publishing, source
